Skip to content

RESP-FIT: Technology-Enhanced Self-Management in COPD

RESP-FIT: Technology-Enhanced Self-Management in COPD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03652662
Acronym
RESP-FIT
Enrollment
34
Registered
2018-08-29
Start date
2018-01-18
Completion date
2020-01-13
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Brief summary

30 adults, aged 40 and older with mild to moderate COPD, will be recruited for this study. Participants must be willing to continually wear a FitBit activity monitor, have access to a smartphone or Wi-Fi/Data-enabled iPad, and be willing to complete respiratory muscle strength training exercises as well as reports on their smartphone at least 5 times per week for a 6-week period. Participants will be given a bluetooth inhaler device and a training app (RESP-FIT). This application will collect inhaler data and allows patients to self-report their daily symptoms. The goal of this study is to test whether use of the personalized inhaler device with the app strengthens lung function, promotes physical activity, and improves disease symptom self-management in persons with COPD.

Detailed description

RESP-FIT. The RESP-FIT program is a 6-week respiratory muscle strength training intervention adapted from previous respiratory muscle strength training (RMST) training regimens, consisting of 1) five training days/week using combined inspiratory and expiratory muscle training, consisting of breathing in and out against a combine inspiratory and expiratory muscle strength trainer (IMST/EMST), 2) individualized, progress-based text message training reminders and prompts related to timing and intensification calibration, and 3) use of a Fitbit for remote monitoring of physical activity and hours slept at night. Similar to other muscle strength training programs, exercises are done at regular intervals during the week (5 breaths, 5 times a day, 5 days a week; the participant will receive graphical illustration of RESP-FIT training frequency and intensity achieved, and based on their training regimen, will be prompted and/or reinforced via SMS text messaging). As the use of an accelerometer or remote tracking device alone may affect physical activity, a control group will receive only the Fitbit. This study proposes to assess the feasibility and initial efficacy of RMST by obtaining estimates of variability in fatigue secondary to dyspnea, using a technologically-enhanced RESP-FIT intervention. Our overarching hypothesis is that a training regimen consisting of RMST along with technology-enhanced symptom-tracking will decrease dyspnea, dyspnea-related activity avoidance, and fatigue. Additionally, this application proposes to further develop Smartphone Airway Monitoring System (SAMS) which currently integrates EMA probe questions covering COPD symptoms and preventive care use with the new functions, use in an adult population with COPD, video captured training technique and logging of RMST training sessions. Up to thirty adults with COPD (age over 40) will complete the study and use the SAMS app for 6 weeks in the natural environment. We will evaluate the acceptability, feasibility, adherence, and performance of RESP-FIT + SAMS through quantitative methods to further optimize the app and related study procedures for the next phase of testing (i.e., large scale efficacy RCT).

Interventions

DEVICERESP-FIT

Inspiratory and Expiratory muscle strength training 5 times a week, plus Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)

BEHAVIORALRESP-FIT Comparator

Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)

Sponsors

University of Florida
CollaboratorOTHER
Medical University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

This is a randomized longitudinal controlled observational study. The study will recruit 30 participants and utilize a control group experimental design with dependent pretest and posttest to derive data regarding (1) feasibility and (2) within-participant effect size of the RESP-FIT intervention in terms of satisfaction, use and adherence, technical issues and acceptability, and self-reported symptom severity (dyspnea and fatigue). When completed, 30 adults (15 in each group) will have used SAMS for 6 weeks.

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 40 years of age or older; and * Able to read and write English; and * Diagnosed with mild to moderate COPD (PFT values: FEV1/FVC \<0.7 and FEV1% predicted \< 50% - within the past 6 months); and * Dyspnea score of greater than 2 on the Modified Medical Research Council (MMRC) questionnaire.

Exclusion criteria

* • Pregnant female or less than 1 year post-partum; or * Diagnosed cognitive deficit or observed lack of understanding during the informed consent process; or * Mobility impairment; or * Lack of 3g WiFi access in place of residence; or * Unwillingness to wear physical activity tracker daily, follow protocol, and/ or attend study visits.

Design outcomes

Primary

MeasureTime frameDescription
Intervention Feasibility (Number of Participants Who Adhered to Treatment)through study completion, average of 6 weeksFeasibility of intervention was measured by the number of participants who adhered to treatment and completed the trial (from baseline to final visit follow-up). Treatment acceptability was measured by the Mobile Application Rating Scale. The Mobile Application Rating Scale asks the participant to report the appropriateness of the app for his/her target audience ranging from little or no (1) to very high level of the acceptability measure (5).

Secondary

MeasureTime frameDescription
Change in Self-efficacybaseline, 6 weeksChange in self-efficacy (measured with the PROMIS Self-Efficacy Scale). This measures the individual's confidence in his/her ability to successfully perform specific tasks or behaviors related to one's health, with 0 being not at all confident to 10 being totally confident. The PROMIS adult Self-Efficacy item banks assess self-reported current level of confidence in managing chronic conditions, including confidence in managing daily activities, managing emotions, managing medications and treatments, managing social interactions and managing symptoms.
Change in Fatiguebaseline, 6 weeksChange in fatigue (measured with the PROMIS v1.0 Fatigue Scale). The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like fatigue, a T-score of 60 is one SD worse than average.
Dyspneabaseline, 6 weeksChange in difficulty breathing (measured with the PROMIS v1.0 Dyspnea). Participant can select from 5 items evaluating how shortness of breath over the past 7 days affected ability to do various activities (Getting dressed, walking stairs, household chores, or walking fast pace) ranging from I did not do this, no difficulty, a little difficulty, some difficulty, and much difficulty. A score of 50 is the average for the general population with a standard deviation of 10 as calibration testing was performed on a large sample of the general population. The dyspnea instruments were calibrated on a sample of adults with COPD, so a score of 50 is the average for people with COPD. For the adult PROMIS Dyspnea Severity 10a short form, a raw score of 10 converts to a T-score of 48.8 with a standard error (SE) of 2.0, for an average dyspnea rating. The T-score can range from 29.7-76.7. A higher score represents more dyspnea being measured.

Countries

United States

Participant flow

Participants by arm

ArmCount
RESP-FIT Intervention
Intervention: IMST/EMST Training (5 breaths, 5 times a day, 5 times a week) Fitbit activity monitoring Daily symptom and training log entered into mobile application (SAMS) RESP-FIT: Inspiratory and Expiratory muscle strength training 5 times a week, plus Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
15
RESP-FIT Comparator
Active Comparator: Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS) RESP-FIT Comparator: Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
15
Total30

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up10
Overall StudyWithdrawal by Subject21

Baseline characteristics

CharacteristicRESP-FIT InterventionTotalRESP-FIT Comparator
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants5 Participants4 Participants
Age, Categorical
Between 18 and 65 years
14 Participants25 Participants11 Participants
Age, Continuous62 years58 years53 years
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
15 Participants30 Participants15 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Forced Expiratory Volume by spirometry55.7 L/sec
STANDARD_DEVIATION 17
55.6 L/sec
STANDARD_DEVIATION 17.2
55.5 L/sec
STANDARD_DEVIATION 17.4
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
4 Participants8 Participants4 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
11 Participants22 Participants11 Participants
Region of Enrollment
United States
15 participants30 participants15 participants
Sex: Female, Male
Female
10 Participants19 Participants9 Participants
Sex: Female, Male
Male
5 Participants11 Participants6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 150 / 15
other
Total, other adverse events
0 / 150 / 15
serious
Total, serious adverse events
0 / 152 / 15

Outcome results

Primary

Intervention Feasibility (Number of Participants Who Adhered to Treatment)

Feasibility of intervention was measured by the number of participants who adhered to treatment and completed the trial (from baseline to final visit follow-up). Treatment acceptability was measured by the Mobile Application Rating Scale. The Mobile Application Rating Scale asks the participant to report the appropriateness of the app for his/her target audience ranging from little or no (1) to very high level of the acceptability measure (5).

Time frame: through study completion, average of 6 weeks

Population: 15 participants were initially enrolled in both groups, 13 participants in the intervention group completed the trial, and 14 in the comparator group.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
RESP-FIT InterventionIntervention Feasibility (Number of Participants Who Adhered to Treatment)13 Participants
RESP-FIT ComparatorIntervention Feasibility (Number of Participants Who Adhered to Treatment)14 Participants
Secondary

Change in Fatigue

Change in fatigue (measured with the PROMIS v1.0 Fatigue Scale). The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like fatigue, a T-score of 60 is one SD worse than average.

Time frame: baseline, 6 weeks

ArmMeasureValue (MEAN)Dispersion
RESP-FIT InterventionChange in Fatigue61.8 score on a scaleStandard Deviation 8.8
RESP-FIT ComparatorChange in Fatigue57.8 score on a scaleStandard Deviation 8.7
Secondary

Change in Self-efficacy

Change in self-efficacy (measured with the PROMIS Self-Efficacy Scale). This measures the individual's confidence in his/her ability to successfully perform specific tasks or behaviors related to one's health, with 0 being not at all confident to 10 being totally confident. The PROMIS adult Self-Efficacy item banks assess self-reported current level of confidence in managing chronic conditions, including confidence in managing daily activities, managing emotions, managing medications and treatments, managing social interactions and managing symptoms.

Time frame: baseline, 6 weeks

ArmMeasureValue (MEAN)Dispersion
RESP-FIT InterventionChange in Self-efficacy6.0 score on a scaleStandard Deviation 1.9
RESP-FIT ComparatorChange in Self-efficacy6.7 score on a scaleStandard Deviation 2.3
Secondary

Dyspnea

Change in difficulty breathing (measured with the PROMIS v1.0 Dyspnea). Participant can select from 5 items evaluating how shortness of breath over the past 7 days affected ability to do various activities (Getting dressed, walking stairs, household chores, or walking fast pace) ranging from I did not do this, no difficulty, a little difficulty, some difficulty, and much difficulty. A score of 50 is the average for the general population with a standard deviation of 10 as calibration testing was performed on a large sample of the general population. The dyspnea instruments were calibrated on a sample of adults with COPD, so a score of 50 is the average for people with COPD. For the adult PROMIS Dyspnea Severity 10a short form, a raw score of 10 converts to a T-score of 48.8 with a standard error (SE) of 2.0, for an average dyspnea rating. The T-score can range from 29.7-76.7. A higher score represents more dyspnea being measured.

Time frame: baseline, 6 weeks

ArmMeasureValue (MEAN)Dispersion
RESP-FIT InterventionDyspnea58.9 score on a scaleStandard Deviation 8.8
RESP-FIT ComparatorDyspnea55.4 score on a scaleStandard Deviation 10.3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026